In Wednesday’s Wall Street session, Novavax, Inc (NASDAQ:NVAX) shares traded at $7.15, down -1.52% from the previous session.
NVAX stock price is now 7.93% away from the 50-day moving average and -20.32% away from the 200-day moving average. The market capitalization of the company currently stands at $1.16B.
With the price target of $19, BTIG Research recently initiated with Buy rating for Novavax, Inc (NASDAQ: NVAX). On July 30, 2024, JP Morgan Downgraded its previous ‘Neutral’ rating to ‘Underweight’ on the stock keeping its target price maintained at $8, while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, YOUNG JAMES F, Former Director bought 10,000 shares of the company’s stock on May 19 ’25. The stock was bought for $75,883 at an average price of $7.59. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 14 ’25, Former Director YOUNG JAMES F bought 4,000 shares of the business’s stock. A total of $24,406 was incurred on buying the stock at an average price of $6.10. A total of 8.87% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc has had a low of $5.01 and a high of $23.86. According to the stock market information, the enterprise value for the company is $655267904, which is based on a 2.70 price-to-earnings ratio, a 0.04 price-to-earnings-growth ratio, and a beta of 2.77. The fifty day moving average price for NVAX is $6.6248 and a two-hundred day moving average price translates $8.9733 for the stock.
The latest earnings results from Novavax, Inc (NASDAQ: NVAX) was released for 2025-03-31.
